473927-63-8 Usage
Description
Ethyl (2Z)-chloro[(4-methoxyphenyl)hydrazono]ethanoate is an organic compound that serves as a versatile intermediate in the synthesis of various organic and pharmaceutical compounds. It is characterized by its unique molecular structure, which includes a chloro group, a hydrazono group, and an ethyl ester group. Ethyl (2Z)-chloro[(4-methoxyphenyl)hydrazono]ethanoate is primarily used in laboratory research and development, as well as in the chemical and pharmaceutical production processes.
Uses
Used in Organic Synthesis:
Ethyl (2Z)-chloro[(4-methoxyphenyl)hydrazono]ethanoate is used as an organic synthesis intermediate for the preparation of a wide range of organic compounds. Its unique molecular structure allows it to participate in various chemical reactions, making it a valuable building block in the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
Ethyl (2Z)-chloro[(4-methoxyphenyl)hydrazono]ethanoate is used as a pharmaceutical intermediate in the development of new drugs and pharmaceutical products. Its ability to be incorporated into the molecular structures of various pharmaceutical compounds makes it an essential component in the drug discovery and development process.
Used in Laboratory Research and Development:
Ethyl (2Z)-chloro[(4-methoxyphenyl)hydrazono]ethanoate is used in laboratory research and development for the exploration of new chemical reactions and the synthesis of novel compounds. Its unique properties and reactivity make it a valuable tool for researchers working in the fields of organic and pharmaceutical chemistry.
Used in Chemical Production Processes:
Ethyl (2Z)-chloro[(4-methoxyphenyl)hydrazono]ethanoate is used in chemical production processes to manufacture a variety of chemical products. Its versatility as an intermediate allows it to be incorporated into the production of various chemicals, contributing to the efficiency and effectiveness of these processes.
Synthesis
Preparation of ethyl (2Z)-chloro[(4-methoxyphenyl)hydrazono]ethanoate To p-anisidine (16 g, 0.129 mol) in conc. HCL (40 mL), 100 mL) H2O, cooled to -5° C. and sodium nitrite (9.4 g, 0.136 mol) in H2O (60 mL) was added. The reaction mixture was stirred at -5° C. for 20 min and a mixture of ethylchloroacetoacetate (22 g, 0.133 mol), ethanol (100 mL), sodiumacetate (32 g, 0.389 mmol), and H2O (400 mL) was added. The reaction was allowed to warm up to room temperature and stirred for 2h. The product precipitated as a black solid. It was filtered and dried (30 g). 1H-NMR (CDCl3) δ 8.28 (s, 1H), 7.18 (d, 2H), 6.90 (d, 2H), 4.41 (q, 2H), 3.80 (s, 3H), 1.42 (t, 3H) ppm.
Check Digit Verification of cas no
The CAS Registry Mumber 473927-63-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,3,9,2 and 7 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 473927-63:
(8*4)+(7*7)+(6*3)+(5*9)+(4*2)+(3*7)+(2*6)+(1*3)=188
188 % 10 = 8
So 473927-63-8 is a valid CAS Registry Number.
473927-63-8Relevant articles and documents
Preparation method of (Z)-[(4-methoxyphenyl)hydrazono]ethyl chloroacetate
-
Paragraph 0023; 0024; 0025; 0026-0030, (2019/07/16)
The invention discloses a preparation method of intermediate (Z)-[(4-methoxyphenyl)hydrazono]ethyl chloroacetate of apixaban. The method uses p-methoxyaniline and ethyl chloroacetate as starting materials to prepare the product. According to the synthetic method provided by the invention, the product prepared by using the synthetic method has high purity, stable quality, and a high yield; and thesynthetic process is simple, the reaction conditions are mild, the reaction operation is simple and convenient, and the method is green and environmentally friendly and can meet industrialized production requirements of the product.
Process for the preparation of apixaban
-
Page/Page column 19, (2017/04/18)
A crystalline Form N-1 of apixaban substantially free from one or more of: 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid; 7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-1-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; or methyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate, relative to apixaban by area percentage of HPLC and having a mean particle size equal to or greater than 100 μm.
PROCESS FOR THE PREPARATION OF APIXABAN
-
Paragraph 17, (2015/11/10)
The present disclosure provides processes and intermediates for the preparation of apixaban.
